Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Should You Ignore the Nuclear Hype and Buy This Instead?

2026-08-06 14:30 • The Motley Fool Positive Axe Cap view: Selective

While nuclear power is experiencing renewed interest due to AI-driven electricity demand, the article argues that investors shouldn't focus solely on nuclear stocks. Instead, NextEra Energy offers broader exposure to the entire electricity demand trend through its diversified portfolio of nuclear, renewable, natural gas, and grid infrastructure assets. NextEra's regulated utility FPL is forecasting 8 gigawatts of large-load demand by 2032, potentially requiring $16 billion in infrastructure investment that could generate over $1 billion in annual pretax earnings.

Axe note: NextEra’s broad energy portfolio offers a smoother ride than pure nuclear plays in capturing rising electricity demand.

Why Honeywell Aerospace Stock Crashed After Earnings

2026-08-06 14:24 • The Motley Fool Negative Axe Cap view: Selective

Honeywell Aerospace stock plunged 20.8% after missing earnings expectations in its first report as a standalone company. The aerospace supplier reported EPS of $1.87 versus expected $2.13, with pro forma earnings declining 32% year-over-year. Management cited supply constraints limiting growth and lowered H2 2026 guidance to 5% sales growth, though CEO noted strong secular trends and customer demand.

Axe note: Honeywell’s new aerospace spinoff missed earnings and lowered sales guidance, dragging its stock down sharply despite strong demand.

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

2026-08-06 14:21 • The Motley Fool Neutral Axe Cap view: Neutral

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

Axe note: Despite an 18.6% fall in July on cash burn fears, Viking Therapeutics' phase 3 progress keeps long-term potential alive.

See all market stories →

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand